Who Paid My Doc
Michelle Lally
Infectious Disease Providence, RI Medical Doctor
NPI 1780638015 CMS profile 556210
164 Summit Ave, Fain Bldg., Suite E, Providence, RI 02906
General payments
$1,376
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Michelle Lally of Providence, RI is reported in the CMS Open Payments database as having received $1,376 across 20 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 67th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $494 | 14 | |
| 2019 | General | $882 | 6 |
Beside peers
- Michelle Lally
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Michelle Lally were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Michelle Lally | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $882 | $190 | $60–$862 | $163 |
| 2020 | $494 | $124 | $32–$606 | $114 |
| 2021 | $0 | $148 | $38–$905 | $132 |
| 2022 | $0 | $166 | $50–$834 | $149 |
| 2023 | $0 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
73
Drug cost
$49,778
Branded share of claims
50.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 12 | $49,333 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 11 | $209 | |
| Doxycycline Monohydrate | Generic | 19 | $102 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 14 | $99 | |
| Prednisone | Generic | 17 | $35 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
20 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Rhode Island
Related records
Infectious Disease in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.